Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 86

1.

Bisphosphonate Treatment Ameliorates Chemotherapy-Induced Bone and Muscle Abnormalities in Young Mice.

Essex AL, Pin F, Huot JR, Bonewald LF, Plotkin LI, Bonetto A.

Front Endocrinol (Lausanne). 2019 Nov 19;10:809. doi: 10.3389/fendo.2019.00809. eCollection 2019.

2.

Age- and sex-dependent role of osteocytic pannexin1 on bone and muscle mass and strength.

Aguilar-Perez A, Pacheco-Costa R, Atkinson EG, Deosthale P, Davis HM, Essex AL, Dilley JE, Gomez L, Rupert JE, Zimmers TA, Thompson RJ, Allen MR, Plotkin LI.

Sci Rep. 2019 Sep 25;9(1):13903. doi: 10.1038/s41598-019-50444-1.

3.

Osteocytic miR21 deficiency improves bone strength independent of sex despite having sex divergent effects on osteocyte viability and bone turnover.

Davis HM, Deosthale PJ, Pacheco-Costa R, Essex AL, Atkinson EG, Aref MW, Dilley JE, Bellido T, Ivan M, Allen MR, Plotkin LI.

FEBS J. 2019 Sep 18. doi: 10.1111/febs.15066. [Epub ahead of print]

PMID:
31532878
4.

High mobility group box 1 protein regulates osteoclastogenesis through direct actions on osteocytes and osteoclasts in vitro.

Davis HM, Valdez S, Gomez L, Malicky P, White FA, Subler MA, Windle JJ, Bidwell JP, Bruzzaniti A, Plotkin LI.

J Cell Biochem. 2019 Oct;120(10):16741-16749. doi: 10.1002/jcb.28932. Epub 2019 May 20.

PMID:
31106449
5.

Glucocorticoid-Induced Bone Fragility Is Prevented in Female Mice by Blocking Pyk2/Anoikis Signaling.

Sato AY, Cregor M, McAndrews K, Li T, Condon KW, Plotkin LI, Bellido T.

Endocrinology. 2019 Jul 1;160(7):1659-1673. doi: 10.1210/en.2019-00237.

PMID:
31081900
6.

Molecular signaling in bone cells: Regulation of cell differentiation and survival.

Plotkin LI, Bruzzaniti A.

Adv Protein Chem Struct Biol. 2019;116:237-281. doi: 10.1016/bs.apcsb.2019.01.002. Epub 2019 Feb 4.

PMID:
31036293
7.

Short-term pharmacologic RAGE inhibition differentially affects bone and skeletal muscle in middle-aged mice.

Davis HM, Essex AL, Valdez S, Deosthale PJ, Aref MW, Allen MR, Bonetto A, Plotkin LI.

Bone. 2019 Jul;124:89-102. doi: 10.1016/j.bone.2019.04.012. Epub 2019 Apr 24.

PMID:
31028960
8.

Chronic Treatment with Multi-Kinase Inhibitors Causes Differential Toxicities on Skeletal and Cardiac Muscles.

Huot JR, Essex AL, Gutierrez M, Barreto R, Wang M, Waning DL, Plotkin LI, Bonetto A.

Cancers (Basel). 2019 Apr 23;11(4). pii: E571. doi: 10.3390/cancers11040571.

9.

RAGE Signaling in Skeletal Biology.

Plotkin LI, Essex AL, Davis HM.

Curr Osteoporos Rep. 2019 Feb;17(1):16-25. doi: 10.1007/s11914-019-00499-w. Review.

PMID:
30685821
10.

The Importance of Connexin 43 in Enamel Development and Mineralization.

Al-Ansari S, Jalali R, Plotkin LI, Bronckers ALJJ, DenBesten P, Zhang Y, Raber-Durlacher JE, de Lange J, Rozema FR.

Front Physiol. 2018 Jun 26;9:750. doi: 10.3389/fphys.2018.00750. eCollection 2018.

11.

Response to R. L. Nevin "Considerations in the repurposing of mefloquine for prevention and treatment of osteoporosis".

Davis HM, Pacheco-Costa R, Plotkin LI.

Bone. 2018 Sep;114:306. doi: 10.1016/j.bone.2018.07.005. Epub 2018 Jul 9. No abstract available.

PMID:
30003962
12.

Cx43 overexpression in osteocytes prevents osteocyte apoptosis and preserves cortical bone quality in aging mice.

Davis HM, Aref MW, Aguilar-Perez A, Pacheco-Costa R, Allen K, Valdez S, Herrera C, Atkinson EG, Mohammad A, Lopez D, Harris MA, Harris SE, Allen M, Bellido T, Plotkin LI.

JBMR Plus. 2018 Jul;2(4):206-216. doi: 10.1002/jbm4.10035. Epub 2018 Jan 18.

13.

Reversal of loss of bone mass in old mice treated with mefloquine.

Pacheco-Costa R, Davis HM, Atkinson EG, Dilley JE, Byiringiro I, Aref MW, Allen MR, Bellido T, Plotkin LI.

Bone. 2018 Sep;114:22-31. doi: 10.1016/j.bone.2018.06.002. Epub 2018 Jun 5.

14.

microRNAs and connexins in bone: interaction and mechanisms of delivery.

Plotkin LI, Pacheco-Costa R, Davis HM.

Curr Mol Biol Rep. 2017 Jun;3(2):63-70. doi: 10.1007/s40610-017-0058-6. Epub 2017 Apr 25.

15.

Loss of the nutrient sensor TAS1R3 leads to reduced bone resorption.

Eaton MS, Weinstein N, Newby JB, Plattes MM, Foster HE, Arthur JW, Ward TD, Shively SR, Shor R, Nathan J, Davis HM, Plotkin LI, Wauson EM, Dewar BJ, Broege A, Lowery JW.

J Physiol Biochem. 2018 Feb;74(1):3-8. doi: 10.1007/s13105-017-0596-7. Epub 2017 Oct 10.

16.

Connexins and Pannexins in Bone and Skeletal Muscle.

Plotkin LI, Davis HM, Cisterna BA, Sáez JC.

Curr Osteoporos Rep. 2017 Aug;15(4):326-334. doi: 10.1007/s11914-017-0374-z. Review.

17.

Improving Combination Osteoporosis Therapy in a Preclinical Model of Heightened Osteoanabolism.

Shao Y, Hernandez-Buquer S, Childress P, Stayrook KR, Alvarez MB, Davis H, Plotkin LI, He Y, Condon KW, Burr DB, Warden SJ, Robling AG, Yang FC, Wek RC, Allen MR, Bidwell JP.

Endocrinology. 2017 Sep 1;158(9):2722-2740. doi: 10.1210/en.2017-00355.

18.

Genetic deletion of Sost or pharmacological inhibition of sclerostin prevent multiple myeloma-induced bone disease without affecting tumor growth.

Delgado-Calle J, Anderson J, Cregor MD, Condon KW, Kuhstoss SA, Plotkin LI, Bellido T, Roodman GD.

Leukemia. 2017 Dec;31(12):2686-2694. doi: 10.1038/leu.2017.152. Epub 2017 May 22.

19.

Glucocorticoids Induce Bone and Muscle Atrophy by Tissue-Specific Mechanisms Upstream of E3 Ubiquitin Ligases.

Sato AY, Richardson D, Cregor M, Davis HM, Au ED, McAndrews K, Zimmers TA, Organ JM, Peacock M, Plotkin LI, Bellido T.

Endocrinology. 2017 Mar 1;158(3):664-677. doi: 10.1210/en.2016-1779.

20.

Disruption of the Cx43/miR21 pathway leads to osteocyte apoptosis and increased osteoclastogenesis with aging.

Davis HM, Pacheco-Costa R, Atkinson EG, Brun LR, Gortazar AR, Harris J, Hiasa M, Bolarinwa SA, Yoneda T, Ivan M, Bruzzaniti A, Bellido T, Plotkin LI.

Aging Cell. 2017 Jun;16(3):551-563. doi: 10.1111/acel.12586. Epub 2017 Mar 19.

21.

High glucose alters the secretome of mechanically stimulated osteocyte-like cells affecting osteoclast precursor recruitment and differentiation.

Maycas M, Portolés MT, Matesanz MC, Buendía I, Linares J, Feito MJ, Arcos D, Vallet-Regí M, Plotkin LI, Esbrit P, Gortázar AR.

J Cell Physiol. 2017 Dec;232(12):3611-3621. doi: 10.1002/jcp.25829. Epub 2017 Apr 25.

22.

Connexin37 deficiency alters organic bone matrix, cortical bone geometry, and increases Wnt/β-catenin signaling.

Pacheco-Costa R, Kadakia JR, Atkinson EG, Wallace JM, Plotkin LI, Reginato RD.

Bone. 2017 Apr;97:105-113. doi: 10.1016/j.bone.2017.01.010. Epub 2017 Jan 16.

PMID:
28096061
23.

Erratum: Osteocytic signalling pathways as therapeutic targets for bone fragility.

Plotkin LI, Bellido T.

Nat Rev Endocrinol. 2016 Jul 29. doi: 10.1038/nrendo.2016.126. [Epub ahead of print] No abstract available.

PMID:
27469347
24.

Control of Bone Anabolism in Response to Mechanical Loading and PTH by Distinct Mechanisms Downstream of the PTH Receptor.

Delgado-Calle J, Tu X, Pacheco-Costa R, McAndrews K, Edwards R, Pellegrini GG, Kuhlenschmidt K, Olivos N, Robling A, Peacock M, Plotkin LI, Bellido T.

J Bone Miner Res. 2017 Mar;32(3):522-535. doi: 10.1002/jbmr.3011. Epub 2016 Oct 27.

25.

PTHrP-Derived Peptides Restore Bone Mass and Strength in Diabetic Mice: Additive Effect of Mechanical Loading.

Maycas M, McAndrews KA, Sato AY, Pellegrini GG, Brown DM, Allen MR, Plotkin LI, Gortazar AR, Esbrit P, Bellido T.

J Bone Miner Res. 2017 Mar;32(3):486-497. doi: 10.1002/jbmr.3007. Epub 2016 Oct 24.

26.

Protection From Glucocorticoid-Induced Osteoporosis by Anti-Catabolic Signaling in the Absence of Sost/Sclerostin.

Sato AY, Cregor M, Delgado-Calle J, Condon KW, Allen MR, Peacock M, Plotkin LI, Bellido T.

J Bone Miner Res. 2016 Oct;31(10):1791-1802. doi: 10.1002/jbmr.2869. Epub 2016 Jun 5.

27.

Avenanthramides Prevent Osteoblast and Osteocyte Apoptosis and Induce Osteoclast Apoptosis in Vitro in an Nrf2-Independent Manner.

Pellegrini GG, Morales CC, Wallace TC, Plotkin LI, Bellido T.

Nutrients. 2016 Jul 11;8(7). pii: E423. doi: 10.3390/nu8070423.

28.

Osteocytic signalling pathways as therapeutic targets for bone fragility.

Plotkin LI, Bellido T.

Nat Rev Endocrinol. 2016 Oct;12(10):593-605. doi: 10.1038/nrendo.2016.71. Epub 2016 May 27. Review.

29.

Role of connexins and pannexins during ontogeny, regeneration, and pathologies of bone.

Plotkin LI, Laird DW, Amedee J.

BMC Cell Biol. 2016 May 24;17 Suppl 1:19. doi: 10.1186/s12860-016-0088-6. Review.

30.

Removing or truncating connexin 43 in murine osteocytes alters cortical geometry, nanoscale morphology, and tissue mechanics in the tibia.

Hammond MA, Berman AG, Pacheco-Costa R, Davis HM, Plotkin LI, Wallace JM.

Bone. 2016 Jul;88:85-91. doi: 10.1016/j.bone.2016.04.021. Epub 2016 Apr 23.

31.

Osteocytic connexin 43 is not required for the increase in bone mass induced by intermittent PTH administration in male mice.

Pacheco-Costa R, Davis HM, Atkinson EG, Katchburian E, Plotkin LI, Reginato RD.

J Musculoskelet Neuronal Interact. 2016 Mar;16(1):45-57.

32.

Bidirectional Notch Signaling and Osteocyte-Derived Factors in the Bone Marrow Microenvironment Promote Tumor Cell Proliferation and Bone Destruction in Multiple Myeloma.

Delgado-Calle J, Anderson J, Cregor MD, Hiasa M, Chirgwin JM, Carlesso N, Yoneda T, Mohammad KS, Plotkin LI, Roodman GD, Bellido T.

Cancer Res. 2016 Mar 1;76(5):1089-100. doi: 10.1158/0008-5472.CAN-15-1703. Epub 2016 Feb 1.

33.

Defective cancellous bone structure and abnormal response to PTH in cortical bone of mice lacking Cx43 cytoplasmic C-terminus domain.

Pacheco-Costa R, Davis HM, Sorenson C, Hon MC, Hassan I, Reginato RD, Allen MR, Bellido T, Plotkin LI.

Bone. 2015 Dec;81:632-643. doi: 10.1016/j.bone.2015.09.011. Epub 2015 Sep 26.

34.

Connexins and pannexins in the skeleton: gap junctions, hemichannels and more.

Plotkin LI, Stains JP.

Cell Mol Life Sci. 2015 Aug;72(15):2853-67. doi: 10.1007/s00018-015-1963-6. Epub 2015 Jun 20. Review.

35.

Inhibition of osteocyte apoptosis prevents the increase in osteocytic receptor activator of nuclear factor κB ligand (RANKL) but does not stop bone resorption or the loss of bone induced by unloading.

Plotkin LI, Gortazar AR, Davis HM, Condon KW, Gabilondo H, Maycas M, Allen MR, Bellido T.

J Biol Chem. 2015 Jul 31;290(31):18934-42. doi: 10.1074/jbc.M115.642090. Epub 2015 Jun 17.

36.

Modifications in bone matrix of estrogen-deficient rats treated with intermittent PTH.

Pacheco-Costa R, Campos JF, Katchburian E, de Medeiros VP, Nader HB, Nonaka KO, Plotkin LI, Reginato RD.

Biomed Res Int. 2015;2015:454162. doi: 10.1155/2015/454162. Epub 2015 Jan 28.

37.

Cx43 and mechanotransduction in bone.

Plotkin LI, Speacht TL, Donahue HJ.

Curr Osteoporos Rep. 2015 Apr;13(2):67-72. doi: 10.1007/s11914-015-0255-2. Review.

38.

Osteocytes mediate the anabolic actions of canonical Wnt/β-catenin signaling in bone.

Tu X, Delgado-Calle J, Condon KW, Maycas M, Zhang H, Carlesso N, Taketo MM, Burr DB, Plotkin LI, Bellido T.

Proc Natl Acad Sci U S A. 2015 Feb 3;112(5):E478-86. doi: 10.1073/pnas.1409857112. Epub 2015 Jan 20.

39.

Prevention of glucocorticoid induced-apoptosis of osteoblasts and osteocytes by protecting against endoplasmic reticulum (ER) stress in vitro and in vivo in female mice.

Sato AY, Tu X, McAndrews KA, Plotkin LI, Bellido T.

Bone. 2015 Apr;73:60-8. doi: 10.1016/j.bone.2014.12.012. Epub 2014 Dec 19.

40.

Comment on Osteocytes: masters orchestrators of bone.

Plotkin LI, Bellido T.

Calcif Tissue Int. 2014 Oct;95(4):382-3. doi: 10.1007/s00223-014-9905-0. Epub 2014 Aug 13. No abstract available.

PMID:
25116738
41.

Parathyroid hormone receptor signaling induces bone resorption in the adult skeleton by directly regulating the RANKL gene in osteocytes.

Ben-awadh AN, Delgado-Calle J, Tu X, Kuhlenschmidt K, Allen MR, Plotkin LI, Bellido T.

Endocrinology. 2014 Aug;155(8):2797-809. doi: 10.1210/en.2014-1046. Epub 2014 May 30.

42.

Connexin 43 hemichannels and intracellular signaling in bone cells.

Plotkin LI.

Front Physiol. 2014 Apr 4;5:131. doi: 10.3389/fphys.2014.00131. eCollection 2014. Review.

43.

Osteoblastic protein tyrosine phosphatases inhibition and connexin 43 phosphorylation by alendronate.

Lezcano V, Bellido T, Plotkin LI, Boland R, Morelli S.

Exp Cell Res. 2014 May 15;324(1):30-9. doi: 10.1016/j.yexcr.2014.03.016. Epub 2014 Mar 31.

44.

High bone mass in mice lacking Cx37 because of defective osteoclast differentiation.

Pacheco-Costa R, Hassan I, Reginato RD, Davis HM, Bruzzaniti A, Allen MR, Plotkin LI.

J Biol Chem. 2014 Mar 21;289(12):8508-20. doi: 10.1074/jbc.M113.529735. Epub 2014 Feb 7.

45.

Apoptotic osteocytes and the control of targeted bone resorption.

Plotkin LI.

Curr Osteoporos Rep. 2014 Mar;12(1):121-6. doi: 10.1007/s11914-014-0194-3. Review.

46.

Resorption controls bone anabolism driven by parathyroid hormone (PTH) receptor signaling in osteocytes.

Rhee Y, Lee EY, Lezcano V, Ronda AC, Condon KW, Allen MR, Plotkin LI, Bellido T.

J Biol Chem. 2013 Oct 11;288(41):29809-20. doi: 10.1074/jbc.M113.485938. Epub 2013 Aug 20.

47.

Absence of Cx43 selectively from osteocytes enhances responsiveness to mechanical force in mice.

Bivi N, Pacheco-Costa R, Brun LR, Murphy TR, Farlow NR, Robling AG, Bellido T, Plotkin LI.

J Orthop Res. 2013 Jul;31(7):1075-81. doi: 10.1002/jor.22341. Epub 2013 Mar 11.

48.

Crosstalk between caveolin-1/extracellular signal-regulated kinase (ERK) and β-catenin survival pathways in osteocyte mechanotransduction.

Gortazar AR, Martin-Millan M, Bravo B, Plotkin LI, Bellido T.

J Biol Chem. 2013 Mar 22;288(12):8168-75. doi: 10.1074/jbc.M112.437921. Epub 2013 Jan 28.

49.

Beyond gap junctions: Connexin43 and bone cell signaling.

Plotkin LI, Bellido T.

Bone. 2013 Jan;52(1):157-66. doi: 10.1016/j.bone.2012.09.030. Epub 2012 Oct 2. Review.

50.

Deletion of Cx43 from osteocytes results in defective bone material properties but does not decrease extrinsic strength in cortical bone.

Bivi N, Nelson MT, Faillace ME, Li J, Miller LM, Plotkin LI.

Calcif Tissue Int. 2012 Sep;91(3):215-24. doi: 10.1007/s00223-012-9628-z. Epub 2012 Aug 4.

Supplemental Content

Loading ...
Support Center